Inactive Instrument

Biotoscana Investments S.A. Stock price

Equities

GBIO33

BRGBIOBDR008

Pharmaceuticals

Dynamic Chart
Biotoscana Investments S.A.(BOVESPA:GBIO33) dropped from S&P Global BMI Index CI
1178991 Canada Inc. completed the acquisition of the remaining 48.8% stake in Biotoscana Investments S.A. approximately BRL 540 million. CI
Biotoscana Investments S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Biotoscana Investments S.A. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Tranche Update on Biotoscana Investments S.A.'s Equity Buyback Plan announced on August 14, 2018. CI
Biotoscana Investments S.A. Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Knight Therapeutics Inc. announced Unified Tender Offer to acquire remaining 48.8% stake in Biotoscana Investments S.A. for approximately BRL 450 million. CI
Knight Therapeutics Inc. completed the acquisition of 51.21% stake in Biotoscana Investments S.A. from Advent Cartagena S.a r.l., Essex Woodlands Health Ventures VIII, L.P., Essex Woodlands Health Ventures VIII-A, L.P. and Essex Woodlands Health Ventures VIII-B, L.P. managed by Essex Woodlands Management, Inc., MAZAL INVESTMENT VENTURES LTD., Robert Friedlander and Roberto Guttman. CI
Biotoscana Investments S.A. Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
Biotoscana Investments S.A.‘s Equity Buyback announced on August 14, 2018, has expired with 1,346,300 shares, representing 1.31% for BRL 14.12 million. CI
BIOTOSCANA INVESTMENTS S.A. Announces Change in Management CI
Canada's Knight Therapeutics to acquire Biotoscana control by Nov 29: filing RE
Biotoscana Investments S A : Knight Therapeutics to purchase Biotoscana in $281 million deal RE
Knight Therapeutics Inc. entered into an agreement to acquire 51.21% stake in Biotoscana Investments S.A. from Advent Cartagena S.a r.l., Essex Woodlands Health Ventures VIII, L.P., Essex Woodlands Health Ventures VIII-A, L.P. and Essex Woodlands Health Ventures VIII-B, L.P. managed by Essex Woodlands Management, Inc., MAZAL INVESTMENT VENTURES LTD., Robert Friedlander and Roberto Guttman for approximately BRL 600 million. CI
Biotoscana Confirms Divestiture Negotiations CI
More news
Managers TitleAgeSince
Chief Executive Officer - 19-10-20
Director of Finance/CFO - 19-08-14
Chief Tech/Sci/R&D Officer - 17-12-14
Members of the board TitleAgeSince
Director/Board Member 61 19-11-24
Chairman 55 19-11-28
Director/Board Member - 19-11-24
More insiders
Biotoscana Investments SA is a Luxembourg-based company engaged in the healthcare industry. The Company develops, manufactures and distributes pharmaceutical products. The Company offers drugs for the treatment of infectious and rare diseases, oncology, onco-hematology, special treatments and immunology, among others. Its product development pipeline is divided into two business models: partnership product development, which is focused on building relationships to license and commercialize products that are new to Latin America, and internal product development, which is focused on studying, designing, formulating and manufacturing branded generic products. Apart from the Luxembourg, the Company operates worldwide in a number of countries, including Peru, Argentina and Ecuador, among others.
More about the company
  1. Stock
  2. Equities
  3. Stock Biotoscana Investments S.A. - Sao Paulo